Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 16 November 2017

Orphazyme A/S: Financial calendar

Orphazyme A/S    

Published: 07:00 CET 16-11-2017 /GlobeNewswire /Source: Orphazyme A/S / : ORPHA /ISIN: DK0060911055

Orphazyme A/S: Financial calendar

Company announcement

Orphazyme A/S

No. 6/2017

Ole Maaløes Vej 3


DK-2200 Copenhagen N






Company Registration No. 32266355




16 November 2017


Orphazyme A/S ("Orphazyme" or the "Company") expects to publish financial reports according to the following schedule:

Deadline for submitting shareholder proposals to the Annual General Meeting 

Wednesday 28 February 2018

Annual report for the full year ending 31 December 2017 

Thursday 15 March 2018

Annual General Meeting 2018

Thursday 12 April 2018

Interim report for the period ending 30 June 2018

Tuesday 28 August 2018


The financial reports will upon their release be available at the Company's website, www.orphazyme.com, where information relating to Orphazyme's Annual General Meeting 2018 will also be available in due course prior to the meeting.  


For additional information, please contact 




Anders Vadsholt, CFO

+45 28 98 90 55


About Orphazyme

Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. The Company was founded in 2009 based on early scientific discovery in heat shock proteins ("HSPs"). Since inception, the Company has translated scientific discovery into a late stage clinical development programme. The Company is headquartered in Copenhagen and currently has 30 employees.

The Company focuses on severe and mostly fatal diseases with a high unmet need, and with a particularly strong commitment to neuromuscular diseases and a group of severe genetic diseases called lysosomal storage diseases. The Company plans to pursue development of its lead candidate through to registration in the EU and the United States after which launch and commercialisation is expected to be undertaken by the Company.

The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis ("sIBM") and Amyotrophic Lateral Sclerosis ("ALS"), and two lysosomal storage diseases, Niemann Pick type C ("NPC") and Gaucher disease.

Orphazyme A/S - Financial calendar

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Orphazyme A/S, Ole Maaløes Vej 3, Copenhagen N 2200, Danmark
If you would like to unsubscribe and stop receiving these e-mails click here.